Lymphoma trial pulled before it started: glofitamab hope on hold
NCT ID NCT06670105
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study aimed to see if the drug glofitamab could prevent large B-cell lymphoma from returning in patients who had traces of cancer after standard treatment. It was designed for adults who had completed first-line therapy and still had minimal residual disease. However, the trial was withdrawn before enrolling any participants, so no data were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab
What this could lead to
If it works, this could help prevent lymphoma from coming back in patients who still have traces of the disease after initial treatment.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. It is unclear if glofitamab is effective or safe for this use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.